Nurse Keith Donnelly opens communal wardrobe for hospital mental health patients
The Maroubra local, who lives with bipolar disorder, was seeking treatment for his mental health and found himself with a limited rotation of clothing.
That was until his nurse, Keith Donnelly, showed him through a boutique walk-in wardrobe in a section of the Prince of Wales Hospital with clothing for him to not only peruse but to call his own.
"The selection was good and basically you could browse, pick what you liked and what fitted," Mr Cavanaugh said.
Mr Cavanaugh said that without "Keith's Closet", he would have been stuck with the limited clothes he came in with.
"If I didn't have visitors or other means of getting clothes … I'd be wearing soiled clothes around," he said.
"The feeling when you pick something you like and can wear can make you feel better.
"That's why the closet is so brilliant."
Mr Donnelly said he repeatedly saw mental health patients lack basic necessities while working at hospitals in both Ireland and Australia.
So in 2019, after emigrating to Sydney, he set out to renovate an unused area of the Prince of Wales Hospital into Keith's Closet.
The idea was to provide patients, at any point during their stay, with new and high-end second-hand clothing, toiletries and accessories free of charge in the hope it would make them look and feel good.
"The hardest part really was trying to locate a space, which was a seclusion room," Mr Donnelly said.
"But it was nice to transform that space into something really positive."
The 51-year-old said at first he would source clothing from either his or his wife's wardrobes, but now the public had jumped on board.
"[We get] donations from either Joe or Mary off the street, from sports shops. Clothing companies have also dropped off end-of-season stock," Mr Donnelly said.
This week, inside Shellharbour Hospital on the New South Wales south coast, Mr Donnelly and Health Minister Ryan Park shared a warm embrace as they unveiled the latest instalment of Keith's Closet.
What was once an office space at the entrance to the hospital's mental health ward now features rows of stocked shelves, mirrors, and hand-painted affirmations.
Mr Donnelly said that, since 2019, the program had expanded, with closets at two Sydney hospitals as well as a mobile van service.
He said all donations were sorted by volunteers at a facility in Alexandria.
Mr Park announced $185,000 in funding for the not-for-profit closet last year to help expand its operations after learning of Mr Donnelly's work at a community cabinet meeting.
"This, for me, is probably some of the best $185,000 we'll ever spend as a government," he said.
"What Keith Donnelly has done here is added another layer of support for those people.
"It will be a service that I know I'll be donating to, so if anyone wants an old suit from a politician, I'm sure it'll be the last thing that gets borrowed or picked up."
Mr Donnelly said he planned to unveil facilities at the Malabar Forensic Hospital and Lismore Base Hospital in the coming weeks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
Scott Power: ASX health stocks up in ‘reasonable start' to reporting season
ASX heath sector up 2.33% over past five days, while broader markets ros 1.2% Avita downgrades FY25 guidance and announces $23 million capital raise 'Materially undervalued' CSL due to report FY25 results next week Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. The ASX Health Care Index (ASX:XHJ) has risen 2.33% for the past five days, beating the benchmark S&P/ASX 200 (ASX:XJO) up 1.2% for the same period in what Morgans' senior healthcare analyst Scott Power has described as a "reasonable start" to reporting season. In the large caps, US-focused radiology imaging house Pro Medicus (ASX:PME) jumped ~6% on Thursday after releasing its FY25 results, which co-founder and CEO Dr Sam Hupert dubbed 'the most successful year in the company's history by any measure'. Pro Medicus revenue for FY25 was up 32% to $213 million with underlying profit before tax rising 40.2% to $163.3m and net profit up 39.2% to $115.2m. The company achieved a record year for contract wins, renewals, and additional module sales. Cash and financial assets grew 35.5% to $210.7m, with ProMedicus remaining debt-free. A fully-franked final dividend of 30 cents per share was declared. Morgans maintains a trim rating on Pro Medicus and has raised its 12-month target price to $285 from $280. A favourite among investors Pro Medicus is trading above that target at around $315. "Pro Medicus reported a result in line with our expectations and the share price responded positively up with strong earnings growth forecast for FY26," Power said. However, investors in Cochlear (ASX:COH) weren't tuning in to quite as positive news. The global hearing implant leader's FY25 results released today came in below expectations and its price fell ~2%. Cochlear reported FY25 NPAT of $392m, which was slightly below consensus of $400m but within recently downgraded guidance of A$390–400m. Revenue rose 4% to $2.356 billion, also slightly under expectations. Cochlear implants sales grew 12% to 53,968 units, slightly above consensus, driven by early access to the new Nucleus Nexa system in the EU and APAC. Developed markets grew 6%, below expectations, while emerging markets surged over 20%. Services revenue, which accounts for ~25% of total revenue declined 9% to $609m, impacted by slower uptake of the N8 sound processor launched in 2023 with US "cost of living" pressures flagged as a factor delaying the replacement cycle. The interim dividend was $2.15, beating forecasts. Cochlear has provided NPAT guidance of $435m to $460m for FY26, slightly below consensus of $461m with Morgans forecasting $436m. Avita bandages up after 'poor' Q2 result Dual Nasdaq-listed wounds management house Avita Medical (ASX:AVH) posted what Morgans' healthcare analyst Iain Wilkie described as a "poor result" for Q2 CY25 and also announced a $22m capital raise. Full-year 2025 revenue guidance was downgraded to a range of $76m to $81m compared to previous guidance of $100m to $106m, reflecting growth of ~19% to 27% over full-year 2024 revenue. Avita revenue for Q2 CY25 of US$18.4m was flat QoQ, and up 21% YoY as demand for its flagship spray-on skin treatment Recell fell ~20% due to unresolved reimbursement issues with medicare administrative contractors (MACs) in the US. Net loss for Q2 improved to US$9.9m, down from US$15.4m on pcp but according to Wilkie was "still insufficient to ease near-term cash flow concerns". In a note to clients Wilkie wrote Avita must deliver US$20m per quarter in H2 CY25 to meet the lower end of guidance. Profitability timelines have now also been pushed, with cash flow breakeven expected in Q2 CY26 and GAAP profitability expected in Q3 26, both delayed by one year. "A poor result, and confirms a structural delay in its breakeven trajectory, but we don't see this as a structural derailment," he wrote. "Commentary around resolutions made in July as Medicare contractors initiate pricing and payments is a good sign this is reversing. "Still, hard for investors to stomach yet another downgrade to guidance. He said the key takeaway with Avita's latest results was the US payor system was complicated. Meanwhile, answering concerns about its balance sheet Avita announced on Wednesday a $23m equity raising, by way of a private placement at $1.32 per share, an 11% discount on the previous close. Although capital raising often drags on a share price, Avita's stock jumped as much as 13% as investors welcomed the added breathing room. Morgans maintains a speculative buy on Avita but has downgraded its 12-month price target from $3.78 to $2. EBR's WiSE finds its rhythm with early sales Developer of the WiSE CRT System – the world's only leadless solution for pacing the left side of the heart, EBR Systems (ASX:EBR) has released its Q2 CY25 results, which was largely in line with expectations – per Morgans healthcare analyst Derek Jellinek in a note to clients. Cash burn was down US$2m to US$11.5m, mainly on lower R&D spend with US$87m cash on hand, which Jellinek wrote was adequate funding for more than seven quarters at the current rate. "Notably, June saw ~US$150k in first commercial sales from three WiSE CRT devices across two leading US hospitals, with favourable physician and patient feedback increasing despite no reimbursement, which is still expected later this year," Jellinek wrote. "We continue to view the phased US commercial rollout, with limited market release in Q4 CY25 followed by full commercial launch in CY26, as prudent, balancing adoption with execution quality." EBR was granted US Food and Drug Administration (FDA) approval for the launch of its Wise CRT system in the US in April. Morgans maintains a buy rating on EBR with a 12-month price target of $2.86. Tetratherix gets government grant for manufacturing facility Newly locally listed wound management company Tetratherix (ASX:TTX) has been awarded $3.3m non-dilutive grant from the Australian government's Industry Growth Program to co-fund its manufacturing facility expansion. The funding will be spread across FY26 and FY27 with Tetratherix contributing to the balance of $4m. Following its ASX debut on June 30, the company allocated $10.2m from its IPO funds for manufacturing expansion. The expanded manufacturing will enable the supply of product for the bone regeneration franchise which is on target for US FDA clearance in H2 CY 26. Power said other upcoming catalysts for Tetratherix include a master service agreement executed with an orthopaedic company expected in H1 CY26. An update on recruitment in a pivotal trial for cohort two using its tissue healing product TetraDerm involving surgical incisions in face/neck is also expected also in the H1 CY26. "Its clearly positive news for Tetratherix and we will assume that the saving in manufacturing will be re-allocated to funding other franchises including bone regeneration, tissue spacing, tissue healing," Power said. "TTX's share price is up over 40% since the IPO and we expect the cadence of news flow to maintain investor interest over the coming quarters." Power's Powerplay: 'Materially undervalued' CSL to report FY25 results The ASX's largest healthcare company, CSL (ASX:CSL) is Power's pick of the week, with the blood products giant due to report its FY25 results next Tuesday. In a July note to clients Power's colleague Jellinek wrote that CSL was currently trading at levels significantly below fair value, pricing it as less than a single-division company, with the main Behring division alone justifying a higher valuation and no value assigned to either Seqirus or Vifor. Morgans 'view CSL as materially undervalued' and over the past decade the company had averaged an EV/EBIT multiple of 24.7 times but today it sits at 18.2 times. Strong demand and cost-cutting measures have helped margins recover for CSL Behring, which focuses on rare and serious diseases such as bleeding and immune disorders and made up more than 70% of earnings. Morgans noted CSL's flu vaccines business Seqirus faced short-term uncertainty around vaccine uptake and the impact of vaccine skeptic Robert F Kennedy Jr's position as Health secretary, but demand was still supported by pandemic contracts. Growth in CSL's iron deficiency and kidney care business Vifor, while slower than expected was also showing signs of improvement. "Combined, we estimate an intrinsic value of $196 bn, representing c35% upside from current trading levels," Jellinek wrote. Morgans has a buy rating on CSL and 12-month target price of $303.70. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While EBR Systems is a Stockhead advertiser, the company did not sponsor this article.
ABC News
an hour ago
- ABC News
Tasmania looks to fast-track new antibiotic for farmed salmon as bacterial disease continues to spread
The Tasmanian government is seeking fast-tracked approval for another antibiotic to be used to treat farmed salmon in public waterways as it continues to grapple with an endemic bacterial disease. Piscirickettsia salmonis — or P. salmonis — is continuing to circulate in salmon pens in southern Tasmania after a mass mortality event in the summer, with fears over warmer winter and spring conditions. Crossbench MPs were briefed on Friday, and claim that the urgency was due to a worsening outbreak in at least one part of the D'Entrecasteaux Channel, which they say was confirmed under questioning during the briefing. The government has avoided using the term "outbreak", instead describing the disease as "endemic" in multiple regions and that mortalities have not reached reportable levels at this stage. Farmed salmon were treated with an oxytetracycline antibiotic during the summer outbreak, when globules of fat from dead fish washed up on multiple beaches. The industry is now pushing for the use of an antibiotic called Florfenicol — which would require new approvals — and has been engaging with the government since February. Primary Industries Minister Gavin Pearce said oxytetracycline had "limited uses" and that he wanted to push ahead with Florfenicol. "This is not listed on Australian labels and approved, however, that process is going forward with the authority at the moment," Mr Pearce said. "We're looking at probably four to six weeks by the time we get an interim permit for that use. Tasmania's Natural Resources and Environment Department confirmed that compliance and intelligence gathering was occurring over farmed fish pens in southern Tasmania, to monitor any increased mortalities. Acting chief veterinary officer Deborah McSweyn said the new antibiotic would be administered as a top coat feed, which could spread into the surrounding marine environment. "There is absolutely every chance that it will spread beyond the pens," she said. "That is why we collaborate with the EPA [Environmental Protection Authority] to do really robust and very rigorous testing to monitor those effects." The EPA is developing a monitoring schedule for Florfenicol to determine how it spreads into the marine environment once administered for farmed fish. The EPA publishes monitoring reports online, but does not disclose when antibiotic use begins, leaving it up to salmon companies to disclose. The extent of current fish mortalities has not been publicly released. Under Tasmanian regulations, mortality events are only reported if more than 0.25 per cent of fish die in a pen over three consecutive days. Independent Franklin MP Peter George told ABC Radio Hobart that Premier Jeremy Rockliff contacted him on Thursday night — before the briefing — to disclose concerns about the level of disease in a pen. Ms McSweyn said the level of disease in pens was "very hard to know". "P. salmonis will always be there as an endemic bacteria. "There is no way of being clear of P. salmonis." She said there had not been an increase in antibiotic resistance among farmed salmon, and that testing for this was continuing. When asked if salmon with P. salmonis was continuing to be harvested for human consumption, Ms McSweyn said the disease was endemic. The Natural Resources and Environment Department previously said the bacterium does not pose a risk to human health. Four crossbench MPs — Greens leader Rosalie Woodruff, and independents Mr George, Craig Garland and Kristie Johnston — attended the briefing with agency officials. They were concerned about whether the government had been able to obtain all relevant information from salmon companies over the extent of disease levels and mortalities. Mr George said the industry needed greater reporting conditions over disease spread. "What was made less clear today is exactly the extent of the disease outbreak, and that's because the … multinational fish farms do not have to tell anyone about the extent of the disease," he said. The crossbenchers remain in negotiations with the Liberals and Labor ahead of a no-confidence motion on Tuesday to determine the next premier and government, and again called for greater regulations for the salmon industry. When asked if the ongoing and evolving use of antibiotics was sustainable for the farmed salmon industry, Mr Pearce said it was common in agricultural sectors. "In my humble opinion, science continues to evolve every day," he said. "If I took you back 10 years, most of the antibiotics [and] medication that you would have been prescribed 10 years ago is no longer available." In a statement, industry body Salmon Tasmania said intended new treatments would form part of a range of actions to combat P. salmonis. "New actions include improved vaccines, stronger biosecurity, feed adjustments, on-farm innovations, and new treatment options," the statement reads.
ABC News
2 hours ago
- ABC News
ACT Ambulance Service confirms just four stretchered vehicles in operation one night this week
In the early hours of Thursday morning, there were only four stretchered ambulances on Canberra roads — less than half the ideal number, the chief officer of the ACT Ambulance Service has confirmed. Between 2am and 6:30am, Chief Officer David Dutton said there were four transport stretcher ambulances and three single response units (SRU) covering the Canberra region. SRUs are vehicles staffed by intensive care paramedics, who respond to calls for assistance and can assess whether a stretchered ambulance is required. Transport Workers Union official Ben Sweeney said staffing was on a "knife-edge" within the service. Mr Sweeney said there was "a lot of pressure on the roster at the moment" due to staff illness, but that lower staffing was "far too common an occurrence". Mr Dutton said the hours between Wednesday night and Thursday morning were "challenging" for the service. But he argued it was "incorrect" to say there were only four ambulances on duty — pointing to the three SRUs as additional resources. "We actually had seven ambulance resources available to Canberra," he said. He said those resources were also supported by staff at their communications centre, "which includes an ambulance paramedic or an intensive care paramedic who's able to provide 'hear and treat' or virtual support to both patients and also to our crews on duty". "It's important to understand the reasons why Wednesday night was such a tough night and, up front, I want to acknowledge, for our staff, whether they were on the road or in our communications centre, it was a busy night," he said. "But the reality when there are less than ideal numbers of resources is that everyone that is at work works a little bit harder. "We did have some short-notice unscheduled sick leave on Wednesday night that impacted the number of resources that we were able to provide to the community." Mr Dutton said there were vacancies within the service that they were hopeful of filling soon. Around a dozen graduate paramedics are expected to begin shifts in the coming weeks, and 10 qualified paramedics from interstate will start in Canberra in November. "Many of the challenges that ACT Ambulance faces are being felt by jurisdictions around the country... these are not problems that are unique or special. "We are a growing city with a growing population and our ambulance service will need to grow to meet the high standards of care that we desire to provide. "Our emergency response times, when you benchmark nationally, are the best in Australia, so that is positive and that is encouraging."
